Prof. Avram Hershko, Technion - Israel Institute of Technology, Haifa
Avram Hershko is the Distinguished Professor at the Center for Cancer and Vascular Biology, Faculty of Medicine and Research Institute at the Technion. Prof Hershko is the discoverer (with A. Ciechanover) of the ubiquitin system for which he was awarded the 2004 Nobel Prize in Chemistry, the 2000 Lasker Prize and the 2001 Wolf Prize.

Prof. Aaron Ciechanover, Technion - Israel Institute of Technology, Haifa
Aaron Ciechanover is the Distinguished Professor at the Institute for Research in Medical Sciences at the Technion. Prof. Ciechanover is a pioneer in the discovery of the ubiquitin system for which he was awarded the 2004 Nobel Prize and the 2000 Lasker prize.

Prof. Alfred Goldberg, Harvard Medical School, MA
Alfred Goldberg is Professor of Cell Biology at Harvard Medical School and is a pioneer in the study of intracellular protein degradation and the ubiquitin proteasome pathway. Professor Goldberg initiated the research program and founded the company that developed the proteasome inhibitor, Velcade, which is now widely used in the treatment of hematological cancers.

Prof. Mark Hochstrasser, Yale University, CT
As a leading authority in the ubiquitin field, Prof. Hochstrasser has published over 50 papers including major reviews in the field. His major research interests include the mechanism of proteasome-mediated proteolysis and regulation by the small ubiquitin modifier (SUMO).

Prof. Yinon Ben-Neria, The Hebrew University, Jerusalem
Prof. Ben Neria is a professor at the Lautenberg Center for Immunology at the Hebrew University. Prof. Ben Neriah is a leading authority in the development and regulation of inflammation and the link between inflammation and cancer.

Prof. Michael Brandeis, The Hebrew University, Jerusalem
Prof. Brandeis is a leading authority in cell cycle control and regulation by the ubiquitin system.